IMPROVING LIFE THROUGH BIOSCIENCE
Delivering new discoveries advancing regenerative medicine...
...Through tireless effort and dedication of pioneers in regenerative medicine...
...Expanding applications to human and animal degenerative medical conditions
Regenerative medicine has been called the “next evolution of medical treatments,” by the U.S. Department of Health and Human Services. “With its potential to heal, this new field of science is expected to revolutionize health care.”
Tithon Biotech is a biotechnology holding company engaged, through its subsidiary corporations, in the development of biomedical solutions addressing various degenerative medical conditions affecting both humans and animals. Our technologies and products result from years of both private and university research and development by pioneers in the field of biotechnology, in collaboration with medical practitioners within various fields of medicine throughout the world.
Our vision is to develop and to provide medical solutions, based upon our advanced new discoveries, to aid both humans and animals around the world who are suffering from various types of degenerative medical conditions.
Through the efforts and dedication of our science team, and those collaborators within the medical community who share our vision and mission, we pursue our vision tirelessly, seeking new means to relieve suffering from degenerative medical conditions.
We have received assignments of various portfolios of proprietary technologies (patented and unpatented trade secrets), each the product of years of research and development work by pioneers in the field of biotechnology, in collaborations with universities and medical practitioners. Additionally, we have been provided access to existing research, R&D capabilities, customer bases for new and existing products, marketing expertise and support systems, distribution channels and operations management systems along with existing relationships with professional “Innovators” and “Early Adopters” of solutions within various human and animal regenerative markets. With full access to all of these resources, we have undertaken the advancement of these technologies through various subsidiary corporations. Each of these subsidiaries has been formed based upon the existing and/or future anticipated markets in which such subsidiary currently or in the future will participate, and each has been granted the rights to the commercial development of the transferred proprietary technologies and products.
Formed with the vision of relieving human suffering resulting from degenerative medical conditions through proprietary technologies and products developed by pioneers in the field of cellular biotechnologies.
Formed with the vision of relieving animal suffering from degenerative medical conditions through proprietary technology and products made available to companion animal and horse owners, and the veterinarian medical community at large.
Formed with the vision of improving human and animal fertility through technology, products, methods and procedures specifically designed to increase female fertility based on proprietary medical discoveries.
Formed with the vision of relieving suffering resulting from autoimmune disease, by providing a line of proprietary diagnostic tests and drugs, based upon a proprietary drug development platform “antigen-specific immunotherapy.”
Tithon Animal Sciences, Inc., was formed with the vision of providing technology and products to companion animal and horse owners and to the veterinarian medical community at large with the goal of relieving companion animals and horses suffering from degenerative medical conditions.
Tithon’s advanced technologies, products, methods, processes and procedures are based on research undertaken by pioneers in the cell therapy research field, assisted by university researchers and practicing veterinarian medical specialists. We are committed to developing revolutionary treatment options for those companion animals and horses suffering from degenerative medical conditions, options that are both safe and effective.
Tithon Human Sciences, Inc.,, was formed with the vision of providing relief from human suffering resulting from degenerative medical conditions, including aging, through proprietary technologies, products, methods, processes and procedures, developed by pioneers in the field of cellular and other biotechnologies.
To this end, we are opening Tithon Regenerative Centers in strategic locations around the world, each dedicated to the development and support of carefully selected and qualified Licensed Clinic Locations, each offering Tithon’s advanced technologies, products, methods, processes and procedures in their practice of medicine.
Tithon Life Sciences, Ltd., was formed with the vision of improving human and animal fertility. We have recently developed technologies, products, processes, methods and procedures specifically designed to increase female fertility based on proprietary medical discoveries useful in diagnosing and treating maternal immune response to paternal antigens; and a method for harvesting and processing a distinct population of peripheral blood derived pluripotent stem cells (PBD-PSC) shown useful in improving ovarian function and the thickness and receptivity of endometrium tissue.
Tithon Immunosciences, Inc. was formed with the vision of providing relief from suffering resulting from autoimmune disease, by providing a line of proprietary diagnostic tests and drugs, based upon a proprietary drug-development platform that the Company has labeled “antigen-specific immunotherapy.” Early testing has shown this Antigen-Specific Immunotherapy Technology effective in both diagnosing certain autoimmune conditions and in addressing symptoms related to a number of autoimmune disorders through the desensitization of the body’s immune response to attack of self-tissues by the body’s own antibodies.
CURRENT NEWS AND EVENTS
Tithon Biotech, Inc is pleased to announce that Dr. Charles Mahl, has joined Tithon's Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon Scientific and Medical Advisory Board provides professional knowledge,...read more
Tithon Biotech, Inc. is pleased to announce that Mr. Greg King, has joined Tithon Biotech, Inc., as its Chief Executive Officer. Dr. Vasilis (“Bill”) Paspaliaris, Tithon’s founder and Chairman, commented: “On behalf of the board of directors, I would like...read more
Tithon Biotech, Inc is pleased to announce that Professor Irena Cosic and her husband and business partner Drasko Cosic, pioneers in the field of biomedical engineering and biomolecular electronics have joined Tithon’s Scientific and Medical Advisory Board. Comprised...read more
Tithon Biotech, Inc is pleased to announce that Dr. Terry Grossman, a pioneer in the field of nutritional medicine and longevity has joined Tithon's Scientific and Medical Advisory Board. Comprised of leaders in both research and clinical practice, the Tithon...read more
Thank you to all who attended the First Symposium for the AABRM in Kuala Lumpur 17-18 December 2016, proudly sponsored by Tithon Biotech, Inc. Please see the below video which summarizes the event.read more